27375283|t|Long-term lamivudine therapy in chronic hepatitis B
27375283|a|One to 5 years of therapy of chronic hepatitis B with oral nucleoside analogues result in significant clinical improvements, but effects of more prolonged therapy are not well defined. To describe outcomes of chronic hepatitis B with long-term lamivudine therapy. Forty-two patients with chronic hepatitis B treated with lamivudine were followed for 3.2-19.5 (median = 16.1) years. Therapy was switched to other agents (n = 16) if patients developed lamivudine resistance and relapse of disease. Among 22 HBeAg-positive patients, 17 (77%) became HBeAg negative, of whom 5 (23%) subsequently cleared HBsAg. Among 20 HBeAg-negative patients, 10 (50%) cleared HBsAg. The time to HBsAg clearance ranged from 0.9 to 16.8 (median = 9.3) years. Lamivudine resistance arose in 24 patients (57%) of whom 6 (25%) lost HBsAg. HBsAg clearance was not always accompanied by seroconversion; anti-HBs appearing concurrently in only five patients (33%). Nevertheless, HBsAg loss allowed for stopping therapy in all patients, none re-developing HBsAg or suffering relapse; all having normal alanine aminotransferase levels and no (n = 13) or unquantifiable HBV DNA levels (n = 2) when last seen. In contrast, seven of 27 patients (26%) who remained HBsAg-positive died of liver disease or liver cancer or underwent liver transplantation, all of whom had cirrhosis. Long-term viral suppression with nucleoside analogues leads to HBsAg loss in a substantial proportion of patients, particularly if HBeAg-negative. Serious outcomes during the first 10-20 years of treatment occur largely among patients with pre-existing cirrhosis who do not clear HBsAg with therapy.
27375283	0	28	Long-term lamivudine therapy	T058	UMLS:C0420257
27375283	32	51	chronic hepatitis B	T038	UMLS:C0524909
27375283	70	77	therapy	T058	UMLS:C0087111
27375283	81	100	chronic hepatitis B	T038	UMLS:C0524909
27375283	111	131	nucleoside analogues	T103	UMLS:C1579410
27375283	197	214	prolonged therapy	T058	UMLS:C0420257
27375283	249	257	outcomes	T058	UMLS:C0033325
27375283	261	280	chronic hepatitis B	T038	UMLS:C0524909
27375283	286	314	long-term lamivudine therapy	T058	UMLS:C0420257
27375283	340	359	chronic hepatitis B	T038	UMLS:C0524909
27375283	360	372	treated with	T058	UMLS:C0332293
27375283	373	383	lamivudine	T103	UMLS:C0209738
27375283	434	441	Therapy	T058	UMLS:C0087111
27375283	464	470	agents	T103	UMLS:C1254351
27375283	502	512	lamivudine	T103	UMLS:C0209738
27375283	513	523	resistance	T038	UMLS:C0013203
27375283	528	546	relapse of disease	T038	UMLS:C0277556
27375283	557	571	HBeAg-positive	T033	UMLS:C0392390
27375283	598	612	HBeAg negative	T033	UMLS:C0948827
27375283	643	650	cleared	T038	UMLS:C0312550
27375283	651	656	HBsAg	T103	UMLS:C0019168
27375283	667	681	HBeAg-negative	T033	UMLS:C0948827
27375283	701	708	cleared	T038	UMLS:C0312550
27375283	709	714	HBsAg	T103	UMLS:C0019168
27375283	728	733	HBsAg	T103	UMLS:C0019168
27375283	734	743	clearance	T038	UMLS:C0312550
27375283	790	800	Lamivudine	T103	UMLS:C0209738
27375283	801	811	resistance	T038	UMLS:C0013203
27375283	860	865	HBsAg	T103	UMLS:C0019168
27375283	867	872	HBsAg	T103	UMLS:C0019168
27375283	873	882	clearance	T038	UMLS:C0312550
27375283	929	937	anti-HBs	T058	UMLS:C0948254
27375283	1004	1009	HBsAg	T103	UMLS:C0019168
27375283	1036	1043	therapy	T058	UMLS:C0087111
27375283	1080	1085	HBsAg	T103	UMLS:C0019168
27375283	1099	1106	relapse	T038	UMLS:C0277556
27375283	1126	1157	alanine aminotransferase levels	T058	UMLS:C0201836
27375283	1192	1206	HBV DNA levels	T058	UMLS:C3641250
27375283	1284	1298	HBsAg-positive	T033	UMLS:C0149709
27375283	1299	1303	died	T033	UMLS:C1306577
27375283	1307	1320	liver disease	T038	UMLS:C0023895
27375283	1324	1336	liver cancer	T038	UMLS:C0345904
27375283	1350	1371	liver transplantation	T058	UMLS:C0023911
27375283	1389	1398	cirrhosis	T038	UMLS:C0023890
27375283	1410	1415	viral	T005	UMLS:C0042776
27375283	1416	1427	suppression	T058	UMLS:C0021079
27375283	1433	1453	nucleoside analogues	T103	UMLS:C1579410
27375283	1463	1468	HBsAg	T103	UMLS:C0019168
27375283	1531	1545	HBeAg-negative	T033	UMLS:C0948827
27375283	1555	1563	outcomes	T058	UMLS:C0033325
27375283	1596	1605	treatment	T058	UMLS:C0087111
27375283	1653	1662	cirrhosis	T038	UMLS:C0023890
27375283	1674	1679	clear	T038	UMLS:C0312550
27375283	1680	1685	HBsAg	T103	UMLS:C0019168
27375283	1691	1698	therapy	T058	UMLS:C0087111